IRCT20170604034325N1已完成2 期
Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis compared to interferons
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 50 years（—）
- 性别
- All
入选标准
- •Relapsing remitting multiple sclerosis according to the McDonald criteria
- •No response or complications to first line multiple sclerosis(MS) drugs
- •Needle phobia
- •Age between 18 - 50
- •Informed consent form
排除标准
- •Significant systemic disease, especially heart disease
- •Lymphopenia
- •Other chronic immune system diseases
- •Varicella zoster, HTLV-1 or TB infection
- •Macular edema
研究者
相似试验
已完成
不适用
Evaluating the efficacy and side effects fingolimod in 3 -year follow-up of patients with recurrent forms of multiple sclerosisIRCT201705108323N15Vice chancellor for research, Kermanshah University of Medical Sciences50
已完成
3 期
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisMultiple SclerosisNCT00355134Novartis1,083
已完成
3 期
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension PhaseMultiple SclerosisNCT00340834Novartis1,292
已完成
3 期
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple SclerosisRelapsing-remitting Multiple SclerosisNCT00289978Novartis1,272
招募中
3 期
Effect of Fingolimod for treatment of COVID-19-induced cytokine stormCondition 1: Coronavirus (COVID-19)-induced pneumonia. Condition 2: Coronavirus (COVID-19)-induced pneumonia.COVID-19, virus identifiedU07.1J12.8IRCT20200317046797N2Tabriz University of Medical Sciences40